Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-860-0045
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.51 million
Profitability
Miscellaneous
Employees71
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable
Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions
What is Concert Pharmaceuticals' stock symbol?
Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."
How were Concert Pharmaceuticals' earnings last quarter?
Concert Pharmaceuticals Inc (NASDAQ:CNCE) posted its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.72) earnings per share for the quarter, beating analysts' consensus estimates of ($0.85) by $0.13. The biotechnology company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.35 million. Concert Pharmaceuticals had a negative return on equity of 55.06% and a negative net margin of 7,291.37%. View Concert Pharmaceuticals' Earnings History.
When is Concert Pharmaceuticals' next earnings date?
What price target have analysts set for CNCE?
7 equities research analysts have issued 1-year price objectives for Concert Pharmaceuticals' shares. Their forecasts range from $8.00 to $25.00. On average, they anticipate Concert Pharmaceuticals' stock price to reach $16.29 in the next year. This suggests a possible upside of 120.1% from the stock's current price. View Analyst Price Targets for Concert Pharmaceuticals.
What is the consensus analysts' recommendation for Concert Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Concert Pharmaceuticals.
What are Wall Street analysts saying about Concert Pharmaceuticals stock?
Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (11/8/2019)
- 2. HC Wainwright analysts commented, "Our price target of $29/share is comprised of $10.39 from CTP-543 in AA + $3.81 from AVP-786 in AD + $8.60 in schizophrenia + $5.75 in cash and is based on a discounted cash flow analysis (2019-2026) using a 12% discount rate and 1% growth rate, in line with the expected discount and growth parameters of a development stage biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition, and pricing." (8/2/2019)
- 3. Mizuho analysts commented, "We do not see earnings as the most meaningful indicator of value for developmental stage biotechs. Catalysts to watch: 1) CTP-543 Phase II data for alopecia areata (AA) is expected in 3Q19, 2) AVP-786 second Phase III trial is expected to complete in Dec 2019, data could be available in early 2020. Concert had $153.8mn at the end of 1Q19 which is expected to support operation through 2H20." (5/3/2019)
Has Concert Pharmaceuticals been receiving favorable news coverage?
Press coverage about CNCE stock has been trending very negative this week, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Concert Pharmaceuticals earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Concert Pharmaceuticals.
Are investors shorting Concert Pharmaceuticals?
Concert Pharmaceuticals saw a drop in short interest in October. As of October 31st, there was short interest totalling 599,700 shares, a drop of 35.4% from the September 30th total of 927,900 shares. Based on an average daily volume of 227,000 shares, the days-to-cover ratio is currently 2.6 days. Currently, 2.8% of the shares of the stock are sold short. View Concert Pharmaceuticals' Current Options Chain.
Who are some of Concert Pharmaceuticals' key competitors?
Some companies that are related to Concert Pharmaceuticals include Flexion Therapeutics (FLXN), Emisphere Technologies (EMIS), Akorn (AKRX), OrganiGram (OGI), Akero Therapeutics (AKRO), Viking Therapeutics (VKTX), DiaMedica Therapeutics (DMCAF), ChemoCentryx (CCXI), Retrophin (RTRX), Intra-Cellular Therapies (ITCI), Myovant Sciences (MYOV), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Synthorx (THOR) and BioDelivery Sciences International (BDSI).
What other stocks do shareholders of Concert Pharmaceuticals own?
Who are Concert Pharmaceuticals' key executives?
Concert Pharmaceuticals' management team includes the folowing people:
- Mr. Richard H. Aldrich Mba, Co-Founder & Chairman (Age 65)
- Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 59)
- Ms. Nancy Stuart, Chief Operating Officer (Age 61)
- Dr. James V. Cassella, Chief Devel. Officer (Age 64)
- Mr. Marc A. Becker, Chief Financial Officer (Age 47)
Who are Concert Pharmaceuticals' major shareholders?
Concert Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Ingalls & Snyder LLC (6.44%), California Public Employees Retirement System (0.65%), Russell Investments Group Ltd. (0.53%), Steward Partners Investment Advisory LLC (0.29%), Alps Advisors Inc. (0.20%) and Rhumbline Advisers (0.14%). Company insiders that own Concert Pharmaceuticals stock include Bvf Partners L P/Il, Heek Christi Van, James V Cassella, Nancy Stuart, Peter Barton Hutt, Richard Aldrich, Ronald W Barrett and Value Fund L P Biotechnology. View Institutional Ownership Trends for Concert Pharmaceuticals.
Which institutional investors are selling Concert Pharmaceuticals stock?
CNCE stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc.. Company insiders that have sold Concert Pharmaceuticals company stock in the last year include Bvf Partners L P/Il and Peter Barton Hutt. View Insider Buying and Selling for Concert Pharmaceuticals.
Which institutional investors are buying Concert Pharmaceuticals stock?
CNCE stock was purchased by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Russell Investments Group Ltd., BB&T Securities LLC, California Public Employees Retirement System, Steward Partners Investment Advisory LLC, Flagship Harbor Advisors LLC and Rhumbline Advisers. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Heek Christi Van and Richard Aldrich. View Insider Buying and Selling for Concert Pharmaceuticals.
How do I buy shares of Concert Pharmaceuticals?
Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Concert Pharmaceuticals' stock price today?
One share of CNCE stock can currently be purchased for approximately $7.40.
How big of a company is Concert Pharmaceuticals?
Concert Pharmaceuticals has a market capitalization of $176.42 million and generates $10.51 million in revenue each year. The biotechnology company earns $-56,020,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Concert Pharmaceuticals employs 71 workers across the globe.View Additional Information About Concert Pharmaceuticals.
What is Concert Pharmaceuticals' official website?
How can I contact Concert Pharmaceuticals?
Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]
MarketBeat Community Rating for Concert Pharmaceuticals (NASDAQ CNCE)
MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
